In the United States, the FDA approved the use of TNF-α inhibitors for the treatment of IBD, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis, with a few of these drugs predicted to have heart complications as potential side effects. This evidence concerns the gene TNF and psoriatic arthritis.